MY138165A - Use of substituted cyclopropane acid derivatives for producing medicaments for treating the metabolic syndrome - Google Patents

Use of substituted cyclopropane acid derivatives for producing medicaments for treating the metabolic syndrome

Info

Publication number
MY138165A
MY138165A MYPI20055838A MYPI20055838A MY138165A MY 138165 A MY138165 A MY 138165A MY PI20055838 A MYPI20055838 A MY PI20055838A MY PI20055838 A MYPI20055838 A MY PI20055838A MY 138165 A MY138165 A MY 138165A
Authority
MY
Malaysia
Prior art keywords
acid derivatives
metabolic syndrome
treating
substituted cyclopropane
producing medicaments
Prior art date
Application number
MYPI20055838A
Inventor
Dieter Dr Kadereit
Siegfried Dr Stengelin
Hubert Dr Heuer
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102004060041A external-priority patent/DE102004060041A1/en
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of MY138165A publication Critical patent/MY138165A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

USE OF SUBSTITUTED CYCLOPROPANE ACID DERIVATIVES FOR PRODUCING MEDICAMENTS FOR TREATING THE ME7ABOLIC SYNDROME 5 THE INVENTION RELATES TO THE USE OF SUBSTITUTED CYCLOPROPANE ACID DERIVATIVES AND OF THEIR PHYSIOLOGICALLY TOLERATED SAILS I-OR PRODUCING MEDICAMENTS FOR THE (REATINENT OFTHE METABOLIC SYNDROME. 10 THE USE OF THE COMPOUNDS OF THE FOLINULA I 0 0 R1,, 0 " 0 @R2 R6 R3 R5 R4- I IN WHICH THE RADICALS HAVE THE STATED MEANINGS, AND OFTHE PHYSIOLOGICALLY TOLERATED SALTS I THEREOF FOR PRODUCING A MEDICAMENT FOR THE TREATMENT OF THE METABOLIC SYNDROME IS 15 DESCRIBED.
MYPI20055838A 2004-12-14 2005-12-13 Use of substituted cyclopropane acid derivatives for producing medicaments for treating the metabolic syndrome MY138165A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004060041A DE102004060041A1 (en) 2004-12-14 2004-12-14 Use of substituted cyclopropane acid derivative having dopamine receptor ligand activity to e.g. treat metabolic syndrome; reduce lipid in the plasma; lower free fatty acid in the plasma; and treat diabetic dyslipidemia
DE102005039245 2005-08-19

Publications (1)

Publication Number Publication Date
MY138165A true MY138165A (en) 2009-04-30

Family

ID=35945136

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20055838A MY138165A (en) 2004-12-14 2005-12-13 Use of substituted cyclopropane acid derivatives for producing medicaments for treating the metabolic syndrome

Country Status (20)

Country Link
US (2) US20080045590A1 (en)
EP (1) EP1827415B1 (en)
JP (1) JP2008523122A (en)
KR (1) KR20070086194A (en)
AR (1) AR052265A1 (en)
AT (1) ATE455543T1 (en)
AU (1) AU2005315975A1 (en)
BR (1) BRPI0519064A2 (en)
CA (1) CA2590024A1 (en)
DE (1) DE502005008929D1 (en)
IL (1) IL183464A0 (en)
MA (1) MA29131B1 (en)
MX (1) MX2007006798A (en)
MY (1) MY138165A (en)
NO (1) NO20073031L (en)
NZ (1) NZ555155A (en)
RU (1) RU2007126842A (en)
TW (1) TW200635575A (en)
UY (1) UY29256A1 (en)
WO (1) WO2006063681A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8053867B2 (en) * 2008-08-20 2011-11-08 Honeywell International Inc. Phosphorous-comprising dopants and methods for forming phosphorous-doped regions in semiconductor substrates using phosphorous-comprising dopants

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4497815B2 (en) * 2001-02-16 2010-07-07 アベンティス・ファーマスーティカルズ・インコーポレイテツド Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands
WO2003053352A2 (en) * 2001-12-20 2003-07-03 Merck & Co., Inc. Therapeutic compounds for treating dyslipidemic conditions
PE20030701A1 (en) * 2001-12-20 2003-08-21 Schering Corp COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS

Also Published As

Publication number Publication date
MX2007006798A (en) 2007-08-07
JP2008523122A (en) 2008-07-03
EP1827415A1 (en) 2007-09-05
IL183464A0 (en) 2007-10-31
NO20073031L (en) 2007-08-03
US20080045590A1 (en) 2008-02-21
WO2006063681A1 (en) 2006-06-22
EP1827415B1 (en) 2010-01-20
AU2005315975A1 (en) 2006-06-22
DE502005008929D1 (en) 2010-03-11
KR20070086194A (en) 2007-08-27
NZ555155A (en) 2009-09-25
CA2590024A1 (en) 2006-06-22
US8222240B2 (en) 2012-07-17
RU2007126842A (en) 2009-01-27
US20090088474A1 (en) 2009-04-02
AR052265A1 (en) 2007-03-07
TW200635575A (en) 2006-10-16
BRPI0519064A2 (en) 2008-12-23
ATE455543T1 (en) 2010-02-15
UY29256A1 (en) 2006-07-31
MA29131B1 (en) 2008-01-02

Similar Documents

Publication Publication Date Title
MX2009006742A (en) Novel compounds.
HK1091121A1 (en) Substituted 2-aminotetralins for the treatment of depressions
IL173203A0 (en) Novel cyano thiazolides, methods for the production thereof, and use thereof as a medicament
MX2009008228A (en) N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase.
WO2008101907A3 (en) N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase
SE0202462D0 (en) Novel use
TW200635582A (en) Medicaments for the treatment or prevention of fibrotic diseases
PT1147110E (en) PIRAZINE (AZA) -INDOL DERIVATIVES
UA85708C2 (en) Benzoxazine-containing pharmaceutical combinations for treating respiratory tract diseases
SG148177A1 (en) Novel cis-imidazolines
DE50311898D1 (en) FREDERICAMYCIN DERIVATIVES AS A MEDICAMENT FOR TUMOR TREATMENT
UA74346C2 (en) Aminodicarboxylic acids derivatives, use thereof and a medicament
EA201001669A1 (en) SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281
UA86977C2 (en) Hydantoin derivatives for the treatment of obstructive airway diseases
EP2039686A4 (en) Dihydropyrimidine compounds and their uses in preparation of medicaments for treating and preventing antiviral diseases
TW200604196A (en) New quinuclidine derivatives and pharmaceutical compositions comprising them
MXPA06013221A (en) Inhalation powder formulations containing enantiomerically pure beta-agonists.
UA85707C2 (en) Benzoxazines for treating respiratory tract diseases
SE0401342D0 (en) Therapeutic compounds
MX2009006913A (en) Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome.
TW200637544A (en) Medicaments for the treatment or prevention of fibrotic diseases
MY148955A (en) Carbamoly-cyclohexanes for treating acute mania
TW200510352A (en) Cycloalkyl substituted amino acid derivatives, processes for their freparation and their use as pharmaceuticals
ATE311866T1 (en) USE OF R-ARYLPROPIONIC ACIDS FOR THE PRODUCTION OF MEDICINAL PRODUCTS FOR THE TREATMENT OF DISEASES OF A RHEUMATIC NATURE
DE602007014193D1 (en) TREATMENT OF PSYCHIATRIC PATIENTS WITH SLEEP DISORDERS AND / OR EXCESSIVE TAGESSLESSNESS WITH PALIPERIDONE